Olivia Vizier

The idea behind Aphaia Pharma is to treat metabolic disease early enough that patients don’t progress to a type 2 diabetes diagnosis.

At Tessera, we are building a broad toolkit of Gene Writers™ to therapeutically edit the genome. Our RNA Gene Writers are designed to efficiently introduce a range of genomic changes from small nucleotide substitutions to exon or gene-sized fragments using all‑RNA compositions.

Flagship and one of the companies it founded, ProFound Therapeutics, said today they’ve agreed to identify new obesity treatments in a collaboration with Pfizer.

Y-mAbs’ Lu-177-based disialoganglioside GD2-targeting program is in phase 1 for small cell lung cancer, melanoma and sarcomas to determine treatment dose, sequence and spacing.

Elixirgen Therapeutics’ Aki Ko joins Erin Harris to detail the company’s Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.

Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections.

COUR nanoparticles (CNPs) induce antigen-specific immune tolerance by harnessing the body’s peripheral immune system.

Tessera Therapeutics, a well-funded startup based outside of Boston, announced Friday that it developed a lipid nanoparticle that shuttles a gene editing therapy directly to the bone marrow of mice.

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company’s gene writing platform and programs more broadly.

Aphaia Pharma, a Swiss biotech, is developing an oral glucose formulation. This aims to restore endogenous signaling mechanisms and metabolic homeostasis in people with obesity, with the goal of mimicking the metabolic effects of bypass surgery without the adverse effects. Its lead drug candidate is currently in a Phase II proof-of-concept study in individuals with

From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired

Following plans to add cohorts in an ongoing Phase II weight-loss study, Aphaia Pharma’s CSO Steffen-Sebastian Bolz says there are now rising challenges with the recruitment of patients in obesity trials.

In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.

So with positive data, and in the summer, we would begin another pivotal trial. This trial will be slightly different in that it will be slightly larger and will include both the US and European sites.

But behind the industry’s first uplisting of 2024, from San Diego biotech Skye Bioscience, is investors’ interest in an area of drug R&D that every therapeutics developer wants in on right now: the next wave of obesity medications.

Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body’s immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine,

Florida-based Syncromune presented the first-ever clinical data from SYNC-T, a personalized platform therapy that uses a drug-device combination, in metastatic castration-resistant prostate cancer.

Arrowhead Pharmaceuticals unveiled Phase IIb data for its investigational RNAi therapy plozasiran at ACC24, demonstrating steep triglyceride reductions at 24 weeks in patients with severely elevated triglyceride levels who are at risk of developing acute pancreatitis.

Aki Ko, chief executive officer at Elixirgen Therapeutics, sat down with NeurologyLive® at the conference to discuss the promise behind the therapy and why it can be successful in treating DMD.

Claris has found dHGF stable for three years at refrigeration temperatures and three months at room temperature

“Aligos is not only supportive of the progress this approval represents but happy to see this class validated as we begin the phase 2a trial of our own highly potent and selective THR-β agonist, ALG-055009.”

With global warming, fungi have become more adapted to higher temperatures like the human body, and with the use of fungicides in farming, fungi are more resistant to treatments.

“Eighty percent of our crop pathogens are fungi,” said Dr. John Rex, chief medical officer for biotech company F2G. “If we’re going to produce crops, especially in these changing environmental conditions, we’re going to need fungicides.”

In a report on the research, the company said that a single oral dose of MM120 met its key secondary endpoint, maintaining “clinically and statistically

AMP immunotherapy enhanced the infiltration and function of TCR-T cells in the tumour microenvironment and led to epitope spreading against diverse tumour targets. Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.

Grifols is readying an approval run at U.S. and European regulators on the back of a phase 3 win for the Spanish plasma medicine producer’s concentrated form of a blood clotting factor.

The trial included 25 people with pancreatic or colorectal cancer who had previously undergone surgery, seven of whom also had received radiation therapy. They were given up to 10 doses of the vaccine known as ELI-002, and the results were promising: 84 percent of all participants had positive T cell responses—and all of those who

Lumos Pharma is developing LUM-201 (ibutamoren) for the treatment of moderate pediatric growth hormone deficiency. PGHD is a rare disorder in which the body doesn’t make enough growth hormone.

Cerevance has shown that “we can tamp down the inflammation response, or the inflammasome, but keep all the other surveillance and other aspects of microglia still functioning as they should.” The company is now conducting a Phase I study of CVN293, with topline data expected in the second quarter of 2024.